Metropolis Healthcare Ltd Q4 FY2022 Concall Summary

Key Takeaways

• Non-COVID business anchors the story: Non-COVID revenue grew 35% YoY for FY22 and 10% QoQ in Q4, even as COVID contribution fell to 12% of revenue from 19% in Q1.
• Margins reset on investment cycle: Q4 EBITDA margin dropped to 27% (vs 35.5% a year ago) as the company layered in spending on digitization, marketing, leadership hires, and lab expansion ahead of revenue.
• Network buildout is accelerating: Metropolis added 16 labs and 509 centers in FY22 and plans another 90 labs and 1,800 centers between FY22 and FY24, with new centers now breaking even in 6–9 months.
• Aggregator shakeout expected: Management sees consolidation in the aggregator space within 6–9 months as funding tightens, and it is steering clear of low-priced wellness in favor of premium, brand-led offerings.
• What to watch next quarter: Whether non-COVID growth normalizes in Q2 as management expects, the pace of margin recovery toward the 27%–28% pre-COVID target, and any sign that the promised unorganized-to-organized shift accelerates.

Non-COVID Growth & Volume Recovery

• Core business momentum: Non-COVID revenue grew 35% YoY for the full year and 10% QoQ in Q4 FY22, recovering from a January–February dip driven by the Omicron wave; March volumes picked up sharply as infections subsided.
• Patient and test volumes: Total patients grew 37% to 1.34 crore and tests grew 35% to 2.57 crore, both driven by the non-COVID portfolio as COVID RT-PCR volumes declined.
• Realization improved ex-COVID: Revenue per patient for non-COVID rose 2% YoY to ₹947 and revenue per test rose 7% to ₹447, helped by upselling and a richer product mix; overall realization looked flat only because COVID tests carry a much lower per-patient value.
• Hitech integration on track: Hitech’s non-COVID business grew 35% to ₹100 crore in FY22, now 81% of its total revenue vs 60% in FY21, with B2C connect driving the improvement.
• Seasonality and base effects: Q1 FY23 non-COVID revenue will grow YoY, but total revenue may optically decline because Q1 FY22 rode a massive COVID wave; management expects more normal non-COVID growth from Q2 onward barring new waves.

Ameera Shah: "I don't have a crystal ball, so it's very difficult to give an exact timeline. But what I can tell you is that we have to understand that when COVID happens, the reason non-COVID comes down is because people are stick with COVID and therefore, that's the disease that takes priority."

Margin Trajectory & Investment Cycle

• Q4 margin compression: EBITDA margin fell to 27% from 35.5% YoY, driven by three deliberate investments: digitization and marketing spend, higher employee costs from strengthening the leadership team and front-end staff, and fixed costs from new labs that had not yet begun generating revenue.
• FY23 margin target: Management is targeting a return to pre-COVID margins of 27%–28%, with the current ~26.2% level expected to inch upward to 27.5%–28% over the next 2–3 quarters.
• Dilution quantified: Network expansion will dilute margins by 0.6%–0.7% and digital/marketing by another 0.5%–0.6%, for a total headwind of roughly 1.2%–1.25%; efficiency projects and automation are expected to fully offset these dilutions.
• Investment spend not fully disclosed: Management declined to provide a specific incremental rupee figure for OpEx, sticking instead to the percentage dilution framework.

Ameera Shah: "And therefore for '23, we believe we would target pre-COVID margin."

Network Expansion & Center Economics

• Aggressive footprint buildout: Metropolis added 16 labs and 509 service centers in FY22 and plans to reach 90 labs and 1,800 centers by FY24; in Mumbai alone, it will add 150 walk-in centers in FY23, taking the network from 341 to 491.
• Faster breakeven: New collection centers in focus cities are now breaking even in 6–9 months, down from 9–12 months historically, driven by better partner selection, stronger brand pull, and improved engagement.
• Productivity rising: Revenue clocked by a new center in its first 12 months has increased with each passing year, and centers opened in 2021 are materially more productive than those opened in 2017.
• Expansion concentrated in core markets: The majority of new labs and centers will be in existing strong geographies where returns and breakeven are faster, with a franchisee mix across North, East, and South India.

Vijender Singh: "Our analysis has shown that the productivity per center in our business has continued to move up higher. That is the revenue clocked by a new center in its first 12 months is increasing in each passing year."

Competitive Landscape & Aggregator Disruption

• Disruption is real but narrow: Management argues that only a small part of the diagnostics business, specifically low-priced wellness, is being disrupted by aggregators; the illness segment, where test quality and doctor trust are paramount, is far less exposed to price-based competition.
• Aggregator consolidation expected: Many aggregators are struggling to secure funding in the current environment, and management expects consolidation in the space within 6–9 months.
• Premium wellness strategy: Metropolis will not compete on low-priced wellness, which it views as a non-sustainable customer-acquisition quest; it will focus on premium wellness using brand, technology, quality, and service, while remaining open to economically sensible partnerships with aggregators.
• Illness spillover opportunity: Management estimates roughly 20% of aggregator-driven wellness customers will have illness needs, and those patients become a target group for Metropolis because they will seek doctors for treatment.
• Unorganized-to-organized shift accelerating: Consolidation from the unorganized segment is expected to happen much faster going forward than in the last 10–15 years, driven by digital health trends and changing consumer behavior.

Ameera Shah: "In health care, it is important to understand that trust, science and consistency of reports and test play a very critical role. In diagnostics, the doctor's medication to a patient is based on the basis of a scientific correct lab report. Also, we have to remember that in the illness space, tests are not commoditized."

Product Mix & B2C Push

• B2C share improving: Revenue share of B2C business in focus cities for non-COVID rose to 60% in FY22 from 58% in FY21, with a near-term target of 65%.
• Wellness contribution rising: Wellness revenue share increased to 9% in FY22 from 7% in FY21, recovering from a COVID-era dip, and reached 10% by Q4; pre-COVID levels were 6%–7%.
• Specialized test share stable: Specialized tests contributed 40% of non-COVID revenue in FY22, down slightly from 42% in FY21, with management expecting improvement as the environment normalizes.
• Home testing footprint widened: Home testing services expanded to 100+ locations from 60 in FY21; non-COVID home testing revenue grew 23%, though overall home testing revenue stayed flat at ₹135 crore due to a sharp drop in COVID home testing.
• Chronic patient loyalty program: A loyalty program for chronic patients is planned to make the business stickier and mitigate competitive pressure on this high-value segment.

Balance Sheet & Capital Allocation

• Hitech acquisition funded and integrating: The ₹636 crore all-cash acquisition closed on 22 October 2021; of the ₹300 crore debt drawn for the deal, roughly ₹42 crore has already been repaid, with the balance targeted for repayment by FY24.
• Working capital mixed: Debtor days improved sharply from 41 to 31 days, but overall working capital days increased from 4 to 14 days due to early payments to creditors.
• Cash generation healthy: Operating cash flow to EBITDA stood at 98%, and the company paid a dividend of roughly ₹40 crore, translating to a 20% PAT payout.
• Acquisition pipeline active: Many deals are available, and management noted that a few competitors who have entered the market are focused on building organic distribution and are not currently competing for acquisitions.

Guidance & Commitments

Key Metrics